Literature DB >> 22833004

Comprehensive model of wild-type and mutant HIV-1 reverse transciptases.

Flavio Ballante1, Ira Musmuca, Garland R Marshall, Rino Ragno.   

Abstract

An enhanced version of COMBINE that uses both ligand-based and structure-based alignment of ligands has been used to build a comprehensive 3-D QSAR model of wild-type HIV-1 reverse transcriptase and drug-resistant mutants. The COMBINEr model focused on 7 different RT enzymes complexed with just two HIV-RT inhibitors, niverapine (NVP) and efavirenz (EFV); therefore, 14 inhibitor/enzyme complexes comprised the training set. An external test set of chiral 2-(alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones (DABOs) was used to test predictability. The COMBINEr model MC4, although developed using only two inhibitors, predicted the experimental activities of the test set with an acceptable average absolute error of prediction (0.89 pK (i)). Most notably, the model was able to correctly predict the right eudismic ratio for two R/S pairs of DABO derivatives. The enhanced COMBINEr approach was developed using only software freely available to academics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833004     DOI: 10.1007/s10822-012-9586-6

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  24 in total

1.  Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzonitriles.

Authors:  Fátima Rodríguez-Barrios; Federico Gago
Journal:  J Am Chem Soc       Date:  2004-03-10       Impact factor: 15.419

2.  2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.

Authors:  Dante Rotili; Alberta Samuele; Domenico Tarantino; Rino Ragno; Ira Musmuca; Flavio Ballante; Giorgia Botta; Ludovica Morera; Marco Pierini; Roberto Cirilli; Maxim B Nawrozkij; Emmanuel Gonzalez; Bonaventura Clotet; Marino Artico; José A Esté; Giovanni Maga; Antonello Mai
Journal:  J Med Chem       Date:  2012-03-26       Impact factor: 7.446

3.  Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.

Authors:  Reynel Cancio; Antonello Mai; Dante Rotili; Marino Artico; Gianluca Sbardella; Imma Clotet-Codina; José A Esté; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  ChemMedChem       Date:  2007-04       Impact factor: 3.466

4.  Atomic solvation parameters applied to molecular dynamics of proteins in solution.

Authors:  L Wesson; D Eisenberg
Journal:  Protein Sci       Date:  1992-02       Impact factor: 6.725

5.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes.

Authors:  J Ren; R Esnouf; E Garman; D Somers; C Ross; I Kirby; J Keeling; G Darby; Y Jones; D Stuart
Journal:  Nat Struct Biol       Date:  1995-04

6.  Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.

Authors:  C Pérez; M Pastor; A R Ortiz; F Gago
Journal:  J Med Chem       Date:  1998-03-12       Impact factor: 7.446

7.  Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1-Infected Patients.

Authors:  Rodger D Macarthur
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

8.  Chiral resolution and molecular modeling investigation of rac-2-cyclopentylthio-6-[1-(2,6-difluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimidin-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class.

Authors:  M Quaglia; A Mai; G Sbardella; M Artico; R Ragno; S Massa; D del Piano; G Setzu; S Doratiotto; V Cotichini
Journal:  Chirality       Date:  2001-02       Impact factor: 2.437

9.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

10.  Substrate-induced stable enzyme-inhibitor complex formation allows tight binding of novel 2-aminopyrimidin-4(3H)-ones to drug-resistant HIV-1 reverse transcriptase mutants.

Authors:  Alberta Samuele; Marcella Facchini; Dante Rotili; Antonello Mai; Marino Artico; Mercedes Armand-Ugón; José A Esté; Giovanni Maga
Journal:  ChemMedChem       Date:  2008-09       Impact factor: 3.466

View more
  3 in total

1.  Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal.

Authors:  Eleonora Proia; Alessio Ragno; Lorenzo Antonini; Manuela Sabatino; Milan Mladenovič; Roberto Capobianco; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2022-06-18       Impact factor: 4.179

2.  Limiting assumptions in molecular modeling: electrostatics.

Authors:  Garland R Marshall
Journal:  J Comput Aided Mol Des       Date:  2013-01-26       Impact factor: 3.686

3.  Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.

Authors:  Manuela Sabatino; Dante Rotili; Alexandros Patsilinakos; Mariantonietta Forgione; Daniela Tomaselli; Fréderic Alby; Paola B Arimondo; Antonello Mai; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2018-01-15       Impact factor: 3.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.